Briefing
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial
In this randomized phase 2 trial, patients with resected stage I-III KRAS-mutated pancreatic cancer were assigned 2:1 to camupepimut (n=96) or standard of care/observation (n=48). The primary disease-free survival endpoint was not met (median 23.8 vs 21.2 months; HR 0.85, P=0.5329). In a post hoc multivariate analysis, baseline ctDNA positivity was associated with worse disease-free survival (adjusted HR 5.99), and a prespecified subgroup analysis reported a disease-free survival HR of 0.51 for camupepimut among ctDNA-negative patients.
- Design: Evidence level 2
- Assay: Not named in the abstract
Nature MedicinePubMed 42919966DOI 10.1038/s41591-026-04734-7